PDF下载 ( 1482 KB)
Clinical effect of systemic chemotherapy combined with transcatheter arterial chemoembolization in treatment of breast cancer with liver metastases
-
摘要:
目的探讨发生肝转移的乳腺癌患者采用全身化疗联合经肝动脉化疗栓塞术（TACE）治疗的效果。方法选取2012年12月-2014年12月于山东省医学科学院附属医院接受治疗的乳腺癌并发肝转移女性患者86例,将其平均分为试验组和对照组。对照组采用全身化疗,试验组给予全身化疗基础上联合TACE治疗,比较2组临床疗效、病灶变化情况以及治疗后患者生活质量评分情况。计量资料组间比较采用t检验,计数资料组间比较采用χ2检验。结果试验组患者治疗的总有效率高于对照组,差异有统计学意义（90.70%vs 58.14%,χ2=13.07,P=0.001）;与对照组相比,试验组患者治疗后肿瘤直径、淋巴结直径较小,差异均有统计学意义（t值分别为4.26、4.63,P值均<0.001）;试验组患者治疗后3、6个月生活质量评分均高于对照组,差异均有统计学意义（t值分别为6.30、3.89,P值均<0.001）。结论对乳腺癌肝转移患者采用全身化疗联合TACE治疗的效果显著,能够改善患者症状,减少药物不良反应,提高生活质量,且安全可靠,值得推广应用。
Abstract:Objective To investigate the clinical effect of systemic chemotherapy combined with transcatheter arterial chemoembolization( TACE) in the treatment of breast cancer with liver metastases. Methods A total of 86 female breast cancer patients with liver metastases who were treated in the Affiliated Hospital of Shandong Academy of Medical Sciences from December 2012 to December 2014 were selected and equally divided into experimental group and control group. The patients in the control group received systemic chemotherapy,and those in the experimental group received systemic chemotherapy combined with TACE. The clinical effect,changes in lesions,and patients' quality of life( QOL) scores after treatment were compared between two groups. The t- test was applied for comparison of continuous data between the two groups,and the chi- square test was applied for comparison of categorical data between the two groups. Results The experimental group had a significantly higher overall response rate than the control group( 90. 70% vs 58. 14%,χ2= 13. 07,P = 0. 001). Compared with the control group,the experimental group had significantly smaller diameters of tumors and lymph nodes after treatment( t = 4. 26 and 4. 63,both P < 0. 001),as well as significantly higher QOL scores at 3 and 6 months after treatment( t = 6. 30 and 3. 89,both P <0. 001). Conclusion Systemic chemotherapy combined with TACE has a significant therapeutic effect in breast cancer patients with liver metastases,and can improve patients' symptoms,reduce adverse drug reactions,and improve QOL. As a safe and reliable therapeutic method,it is worthy of clinical application.
-
Key words:
- breast neoplasms /
- neoplasm metastasis /
- drug therapy /
- chemoembolization,therapeutic
-
[1]RAO ZG,GAO JF,ZHANG BC,et al.Clinical observation of breast cancer liver metastasis after mastectomy by combined treatment of transarterial chemoembolization(TACE)and systemic chemotherapy[J].J Mod Oncol,2013,21(9):1994-1996.(in Chinese)饶智国,高建飞,章必成,等.全身化疗联合肝动脉栓塞化疗治疗乳腺癌术后肝转移的临床疗效观察[J].现代肿瘤医学,2013,21(9):1994-1996. [2]WALKER MS,HASAN M,YIM YM,et al.Retrospective study of the effect of disease progression on patient reported outcomes in HER-2negative metastatic breast cancer patients[J].Health Qual Life Outcomes,2011,9:46. [3]ZHANG P,XU EJ,HUANG Y,et al.Curative effect of radiofrequency ablation combined with chemotherapy for liver metastases from breast cancer in 6 cases[J/CD].Chin J Hepatic Surg:Electronic Edition,2014,3(5):299-302.(in Chinese)张鹏,许尔蛟,黄勇,等.射频消融联合化疗治疗乳腺癌肝转移六例疗效分析[J/CD].中华肝脏外科手术学电子杂志,2014,3(5):299-302. [4]AARONSON NK,AHMEDZAI S,BERGMAN B,et al.The European Organization for research and treatment of cancer QLQ-C30:a quality-of-life instrument for use in international clinical trials in oncology[J].J Natl Cancer Inst,1993,85(5):365-376. [5]LIU CF,YAN JJ,LI J,et al.Partial hepatectomy for liver metastases from breast cancer:a retrospective study of 47 patients[J].Chin J Hepatobiliary Surg,2012,18(6):420-423.(in Chinese)刘才峰,晏建军,李静,等.乳腺癌术后肝脏转移的手术治疗:47例回顾性分析[J].中华肝胆外科杂志,2012,18(6):420-423. [6]DONG Y,KANG LH,GUAN M,et al.Clinical effect and influencing factor analysis of postoperative adjurant therapy for patients with breast cancer[J].J Jilin Univ:Med Edit,2015,41(3):636-642.(in Chinese)董营,康丽花,关萌,等.乳腺癌患者术后辅助治疗的临床效果及其影响因素分析[J].吉林大学学报:医学版,2015,41(3):636-642. [7]LALISANG RI,ERDKAMP FL,RODENBURG CJ.Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer:a randomized phaseⅡstudy of dose-dense and dose-escalated chemotherapy[J].Breast Cancer Res Treat,2011,128(2):437-445. [8]MIN WL,WANG XJ,LIU XX,et al.Diagnosis and treatment of39 cases of breast cancer patients with liver metastases[J].J Mod Oncol,2014,22(7):1592-1594.(in Chinese)闵卫利,王西京,刘小旭,等.39例乳腺癌并肝转移诊治体会[J].现代肿瘤医学,2014,22(7):1592-1594. [9]WU QC.Effect comparison of different chemotherapy regimens of capecitabine in breast cancer liver metastasis[J].China Modern Med,2015,22(11):63-65.(in Chinese)吴庆成.卡培他滨不同化疗方案治疗乳腺癌肝转移的效果对比[J].中国当代医药,2015,22(11):63-65. [10]XIE J,CHEN RP,ZHANG YF,et al.The clinical effects of navelbine plus platinum chemotherapy on recurrent metastatic breast cancer of elderly patients[J].Anti-Tumor Pharm,2015,5(3):209-212.(in Chinese)夏金,陈瑞萍,张彦芳,等.诺维本联合铂类二线化疗治疗老年复发转移性乳腺癌的疗效分析[J].肿瘤药学,2015,5(3):209-212. [11]ZHAO ZB.Surgical treatment for patients with liver metastasis after breast cancer surgery[J].Zhejiang Clin Med J,2012,14(3):268-270.(in Chinese)赵宗彬.乳腺癌术后肝转移患者的手术治疗分析[J].浙江临床医学,2012,14(3):268-270. [12]TSIMBERIDOU AM,LETOURNEAU K,FU S,et al.PhaseⅠclinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement[J].Cancer Chemother Pharmacol,2011,68(1):247-253. [13]ZHAO ZB,JIAN ZY.The Retrospective analysis of the treatment for alone hepatic metastatic breast carcinoma not suitable for excision after the primary lesion removal[J].J Hubei Univ Med,2012,31(3):204-208.(in Chinese)赵宗彬,菅志远.无法手术切除的乳腺癌单纯性肝转移患者治疗的回顾性分析[J].湖北医药学院学报,2012,31(3):204-208. [14]CHEN YL,WANG YF,LIU K,et al.Clinical research on TX and NX regimens in treatment of liver metastasis of breast cancer[J].Matern Child Health Care China,2014,29(34):5695-5697.(in Chinese)陈云兰,王羽丰,刘坤,等.TX与NX方案治疗乳腺癌肝转移的临床研究[J].中国妇幼保健,2014,29(34):5695-5697. [15]HUA YY.Efficacy analysis of intervention for metastatic breast cancer[J].Anti-Tumor Pharm,2011,1(5):462-463,466.(in Chinese)华燕艳.乳腺癌肝转移介入治疗疗效分析[J].肿瘤药学,2011,1(5):462-463,466. [16]GADALETA CD,RANIERI G.Trans-arterial chemoembolization as a therapy for liver tumours:new clinical developments and suggestions for combination with angiogenesis inhibitors[J].Crit Rev Oncol Hematol,2011,80(1):40-53. 期刊类型引用(17)
1. 郭堑，农村立，韦秋芳. 慢性乙型肝炎肝纤维化患者血清Copeptin和PCT表达水平及其临床价值研究. 现代检验医学杂志. 2023(02): 112-117+189 . 
百度学术2. 李初谊，王俊科，李斌，温雪，魏晓静，于晓辉. 血浆置换对慢加急性肝衰竭辅助治疗的效果评价. 海南医学院学报. 2022(16): 1228-1231 . 百度学术3. 王鑫，张国民，牛兴杰，李萍，张冰. 外周血CD14~+CD16~+单核细胞亚群在肝衰竭继发感染患者中的检测价值. 中国免疫学杂志. 2020(09): 1124-1127+1130 . 百度学术4. 姜曼蕾，许飞，胡江玲，罗嘉裕，罗方云. IL-6、CRP、PCT和内毒素预判肝衰竭合并细菌感染风险中的临床价值. 中华医院感染学杂志. 2020(20): 3062-3065 . 百度学术5. 张国民，王鑫，韩智炜，牛兴杰，刘志慧，崔凤梅. 降钙素原、白细胞介素6、sCD14、CD64检测在肝功能衰竭患者诊治中的临床研究. 中国现代医学杂志. 2019(03): 47-51 . 百度学术6. 江艳霞，骆小燕，骆旭航，龚安安，孙爱华. 血清降钙素原在胆管炎危重度早期评估中的价值研究. 中国卫生检验杂志. 2019(04): 462-463+468 . 百度学术7. 张国民，韩智炜，牛兴杰，刘志慧，王鑫. IL-6、CD14、CD64检测在感染所致肝衰竭患者中意义. 现代医学. 2019(02): 137-140 . 百度学术8. 黄波，张炜. 喜炎平注射液联合还原型谷胱甘肽治疗重症烧伤后急性肝功能损伤临床研究. 创伤与急危重病医学. 2019(03): 156-159 . 百度学术9. 杨丽霞，张伦理，赖玲玲，方铭. 腹水中肝素结合蛋白及降钙素原对肝硬化腹水伴自发性细菌性腹膜炎的诊断价值. 临床肝胆病杂志. 2019(06): 1266-1269 . 
本站查看10. 李薇，任小丹，何谦，周荣幸. 血清降钙素原检测对胆道梗阻合并感染者的预测价值. 中华实验和临床感染病杂志(电子版). 2019(03): 245-249 . 百度学术11. 张国民，韩智炜，牛兴杰，刘志慧，崔凤梅，王鑫. PCT、IL-6、CD14、CD64及TNF-α表达对肝衰竭合并医院感染患者预后的影响. 中华医院感染学杂志. 2019(16): 2450-2453 . 百度学术12. 王鑫，张国民，牛兴杰，李萍，张冰. 肝衰竭继发感染患者外周血Toll样受体4及降钙素原、C反应蛋白变化情况分析. 现代消化及介入诊疗. 2019(10): 1084-1087+1094 . 百度学术13. 石春霞，陈倩，王瑶，焦方舟，龚作炯. 肝功能衰竭并感染患者血清正五聚蛋白3和肝素结合蛋白及降钙素原水平变化. 中华实用诊断与治疗杂志. 2019(12): 1188-1190 . 百度学术14. 顾静，王艳，陈丽，徐英，甘建和. HBV相关慢加急性肝衰竭患者血清IL-32和IL-10水平变化及意义. 临床肝胆病杂志. 2018(04): 801-805 . 本站查看15. 王小芳，奉万盛，周红翠，邱咏佳. 血清降钙素原、白细胞计数、C-反应蛋白与细菌血培养联合检测在感染患者中的应用价值. 中国医药导报. 2018(19): 75-78 . 百度学术16. 沈素晶，邓超，李霭文，谭俊青. 不同化学发光检测系统测定PCT结果的相关性分析. 实验与检验医学. 2018(06): 873-875+891 . 百度学术17. 詹金美，林欢，孙家敏. 定量检测血清降钙素原在诊断肝衰竭患者腹腔感染细菌类型中的价值. 中外医疗. 2017(28): 34-36 . 百度学术其他类型引用(1)
-
百度学术
下载:
